BR112019018388A2 - método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno - Google Patents
método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno Download PDFInfo
- Publication number
- BR112019018388A2 BR112019018388A2 BR112019018388A BR112019018388A BR112019018388A2 BR 112019018388 A2 BR112019018388 A2 BR 112019018388A2 BR 112019018388 A BR112019018388 A BR 112019018388A BR 112019018388 A BR112019018388 A BR 112019018388A BR 112019018388 A2 BR112019018388 A2 BR 112019018388A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- film
- fact
- oral
- mtl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762478876P | 2017-03-30 | 2017-03-30 | |
PCT/CA2018/050389 WO2018176149A1 (en) | 2017-03-30 | 2018-03-29 | Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019018388A2 true BR112019018388A2 (pt) | 2020-04-07 |
Family
ID=63673863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019018388A BR112019018388A2 (pt) | 2017-03-30 | 2018-03-29 | método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3600265A1 (de) |
JP (1) | JP2020512309A (de) |
KR (1) | KR20190128637A (de) |
CN (1) | CN110381931A (de) |
AU (1) | AU2018241534A1 (de) |
BR (1) | BR112019018388A2 (de) |
CA (1) | CA3056944A1 (de) |
MX (1) | MX2019010573A (de) |
WO (1) | WO2018176149A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3150213A1 (en) * | 2018-09-14 | 2022-03-19 | Intelgenx Corp. | TREATMENT METHOD AND DEVICE FOR ENHANCED BIOAVAILABILITY OF MONTELUKAST, A LEUCOTRIEN RECEPTOR ANTAGONIST |
US20210393611A1 (en) * | 2018-11-05 | 2021-12-23 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
US11602504B2 (en) * | 2018-11-05 | 2023-03-14 | Intelgenx Corp. | Lipophilic active oral film formulation and method of making the same |
CN110496124A (zh) * | 2019-04-10 | 2019-11-26 | 中山大学附属第五医院 | 治疗脉管畸形的化合物 |
CN114931578A (zh) * | 2022-05-16 | 2022-08-23 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 孟鲁司特在制备用于治疗***性红斑狼疮药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101074271B1 (ko) * | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
KR101077468B1 (ko) * | 2011-03-04 | 2011-11-07 | (주)차바이오앤디오스텍 | 안정한 경구용 속용 필름 제제 |
EA038558B1 (ru) * | 2013-10-14 | 2021-09-14 | Зим Лэбораториз Лимитед | Водорастворимая фармацевтическая пленка с повышенной стабильностью |
US9668970B2 (en) * | 2013-12-02 | 2017-06-06 | Intelgenx Corp. | Film dosage form with extended release mucoadhesive particles |
CN104784157B (zh) * | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | 一种稳定的孟鲁司特口腔薄膜剂 |
-
2018
- 2018-03-29 JP JP2019548270A patent/JP2020512309A/ja active Pending
- 2018-03-29 AU AU2018241534A patent/AU2018241534A1/en not_active Abandoned
- 2018-03-29 BR BR112019018388A patent/BR112019018388A2/pt not_active Application Discontinuation
- 2018-03-29 MX MX2019010573A patent/MX2019010573A/es unknown
- 2018-03-29 EP EP18774366.1A patent/EP3600265A1/de not_active Withdrawn
- 2018-03-29 KR KR1020197025967A patent/KR20190128637A/ko unknown
- 2018-03-29 WO PCT/CA2018/050389 patent/WO2018176149A1/en unknown
- 2018-03-29 CA CA3056944A patent/CA3056944A1/en active Pending
- 2018-03-29 CN CN201880016281.6A patent/CN110381931A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020512309A (ja) | 2020-04-23 |
AU2018241534A1 (en) | 2019-09-26 |
CA3056944A1 (en) | 2018-10-04 |
KR20190128637A (ko) | 2019-11-18 |
EP3600265A1 (de) | 2020-02-05 |
CN110381931A (zh) | 2019-10-25 |
MX2019010573A (es) | 2019-10-24 |
WO2018176149A1 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019018388A2 (pt) | método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno | |
US10722476B2 (en) | Device and method of treating conditions associated with neuroinflammation | |
US20220395452A1 (en) | Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists | |
US20230201130A1 (en) | Lipophilic active oral film formulation and method of making the same | |
CN107567440B (zh) | 焦谷氨酸沃替西汀 | |
US20220362164A1 (en) | Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists | |
CN114272233A (zh) | 一种奥司他韦组合物及其制备方法 | |
CA3017526A1 (en) | Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists | |
EP3849553A1 (de) | Behandlungsverfahren und vorrichtung zur verbesserten bioverfügbarkeit von montelukast, einem leukotrienrezeptorantagonist | |
US20210393611A1 (en) | Lipophilic active oral film formulation and method of making the same | |
US11690829B2 (en) | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder | |
Peter et al. | DESIGN AND EVALUATION OF CARBAMAZEPINE LOZENGES | |
JPWO2021062061A5 (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |